PC945

DRUG5 trials

Sponsors

Pulmocide Limited, Pulmocide Ltd

Conditions

AspergillosisAsthmaBronchiectasisCOPDCystic FibrosisLung Transplant InfectionRefractory IPARefractory Invasive Pulmonary Aspergillosis

Phase 2

The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases

TerminatedNCT03745196

Pulmocide LtdAsthma, Bronchiectasis, COPD +2

Start: 2018-11-15End: 2020-06-01Updated: 2020-06-12

The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis

TerminatedNCT03870841

Pulmocide LtdAspergillosis, Cystic Fibrosis

Start: 2019-04-03End: 2020-06-01Updated: 2021-07-16

The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.

TerminatedNCT03905447

Pulmocide LtdAspergillosis, Lung Transplant Infection

Start: 2019-09-17End: 2020-06-01Updated: 2021-07-16

Phase 3

Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)

TerminatedNCT05238116

Pulmocide LtdRefractory IPA

Start: 2022-06-14End: 2025-12-29Updated: 2026-04-30

A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis (OPERA-T study)

CompletedCTIS2024-511281-36-00

Pulmocide LimitedRefractory Invasive Pulmonary Aspergillosis

Start: 2022-11-17End: 2025-12-19Target: 46Updated: 2025-09-05